On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
June 21, 2024 16:04 ET
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...
The International Food Information Council (IFIC) Releases Annual Food & Health Survey Revealing Rising Consumer Stress, Lagging Consumer Confidence In The U.S. Food Supply
June 20, 2024 10:06 ET
|
International Food Information Council Foundation
Washington, DC, June 20, 2024 (GLOBE NEWSWIRE) -- The International Food Information Council (IFIC) released its 2024 Food & Health Survey today, revealing the perceptions, beliefs, and...
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
June 13, 2024 08:15 ET
|
CERo Therapeutics Holdings, Inc.
Company anticipates near term filing of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO)...
US Gastroenterologists Express Anticipation for Approval of AbbVie’s Skyrizi in Ulcerative Colitis, Projecting Rapid Adoption Post-Launch
June 12, 2024 12:18 ET
|
Spherix Global Insights
EXTON, PA, June 12, 2024 (GLOBE NEWSWIRE) -- Despite being the second IL-23 inhibitor to enter the market, AbbVie’s Skyrizi (risankizumab) is expected to have a substantial impact on ulcerative...
Dream Valley Presents Innovation at SLEEP 2024 to Help Facilitate Deep Sleep
June 11, 2024 09:00 ET
|
Dream Valley
Houston, June 11, 2024 (GLOBE NEWSWIRE) -- Shadow Wang, chief executive officer of Dream Valley, emphasized the importance of deep sleep during his presentation at the SLEEP 2024 event, the 38th...
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
June 11, 2024 08:45 ET
|
FN Media Group LLC
PALM BEACH, Fla., June 11, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - In the last twenty years, the amount of people with multiple sclerosis (MS) in the United States has more than...
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
June 11, 2024 08:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis
June 11, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals receives FDA orphan drug status for tafenoquine to treat acute babesiosis, offering market exclusivity and tax incentives.
Kronos Advanced Technologies Inc Maintains Leadership As The First Public Company To Embrace Shiba Inu: A Leap Into The Future Of E-Commerce Payments
June 10, 2024 15:01 ET
|
Kronos Advanced Technologies Inc.
Los Angeles, CA , June 10, 2024 (GLOBE NEWSWIRE) -- Kronos Advanced Technologies Inc. (OTC: KNOS), a leading innovator in air purification solutions, is thrilled to announce the acceptance of Shiba...
Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
June 06, 2024 09:00 ET
|
Tiziana Life Sciences Ltd.
Qualitative improvements in PET imaging seen in 80% of non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access patients receiving intranasal foralumab for at least 6-months.FDA...